CN115645459A

CN115645459A - Preparation method of cistanche extract, cistanche extract and application

Info

Publication number: CN115645459A
Application number: CN202211100840.6A
Authority: CN
Inventors: 谭余庆; 赵庆贺
Original assignee: Beijing Mingyang Huaxia Technology Co ltd
Current assignee: Beijing Mingyang Huaxia Technology Co ltd
Priority date: 2022-09-09
Filing date: 2022-09-09
Publication date: 2023-01-31
Anticipated expiration: 2042-09-09
Also published as: CN115645459B

Abstract

The invention provides a preparation method of a cistanche extract, the cistanche extract and application, belongs to the field of traditional Chinese medicine extraction, and adopts cistanche which is homologous in medicine and food as a raw material, so that the cistanche extract has the advantages of wide source, low price, easiness in obtaining, good safety and no toxic or side effect on a human body. In the preparation method, the cistanche alcohol extract is separated and purified by adopting macroporous resin, so that the active ingredients in the cistanche can be effectively extracted, wherein the content of echinacoside is 21.51 percent, the process is simple, and the extraction rate is high. The cistanche deserticola extract prepared by the invention can obviously inhibit PDE (PDE) ₅ The protein improves the activity of nitric oxide synthase, thereby effectively treating erectile dysfunction.

Description

Preparation method of cistanche extract, cistanche extract and application

Technical Field

The invention belongs to the technical field of traditional Chinese medicine extraction, and particularly relates to a preparation method of a cistanche extract, the cistanche extract and application of the cistanche extract.

Background

Erectile Dysfunction (ED) is a common clinical disease, which is specifically manifested as decreased libido, inability of penis to be male in a certain time, or sufficient duration, and belongs to the field of impotence in traditional Chinese medicine, and kidney-yang deficiency is a common clinical disease, which is one of the important diseases disturbing men all over the world. Although erectile dysfunction is not a serious fatal disease, the physical function incompleteness brings great psychological stress to patients, can seriously affect the mental and physical states of the patients in daily life, and has impact on self-confidence and living level, even household harmony.

Currently, the most effective therapeutic drug for erectile dysfunction is sildenafil, which has a clinical effective rate of 80% for ED due to various causes, and selectively inhibits phosphodiesterase type v (PDE) by sildenafil ₅ ) The activity is blocked and cGMP is inactivated, so that the penile erection function is enhanced, but a great number of reports prove that sildenafil has adverse reaction and can cause unpredictable physical harm after long-term administration. Nitric Oxide Synthase (NOS) is a major messenger leading to vasodilatation and cavernous body relaxation, and is involved in the induction and maintenance of erection, NOS activity in the cavernous body of the penis is enhanced in an excited state, a large amount of NO is secreted to convert GTP into cGMP, and the activity of an intracellular NO-cGMP signal pathway is enhanced, so that the smooth muscle of the cavernous body is in a relaxed state, and penis erection is induced. Thus, the PDE ₅ And NOS research has attracted widespread attention in the medical community.

Cistanche deserticola, a perennial herb of cistanche genus plant of Orobanchaceae family, is parasitic on the root of haloxylon ammodendron in desert trees, is vegetarian with the reputation of desert ginseng, has extremely high medicinal value, and is classified as a medicinal and edible plant in 2018. Research shows that the cistanche has the effects of tonifying kidney and strengthening yang, relaxing bowel, protecting liver, regulating immunity, resisting tumor, oxidation, fatigue and radiation, protecting nervous system, improving amnesia and the like, so that the pharmacological effects of active ingredients in the cistanche attract extensive attention of researchers.

Disclosure of Invention

In view of the above, the present invention aims to provide a preparation method of cistanche extracts, cistanche extracts and applications thereof.

In order to achieve the above purpose, the invention provides the following technical scheme:

the invention provides an application of cistanche extract in preparing a medicament for treating erectile dysfunction.

The invention also provides a cistanche deserticola extract in preparing PDE ₅ The use of inhibitors.

The invention also provides application of the cistanche salsa extract in preparation of the nitric oxide synthase activator.

The invention also provides a preparation method of the cistanche salsa extract, which comprises the following steps:

pulverizing Cistanchis herba, mixing with ethanol solution 1, extracting, filtering, concentrating filtrate, passing Cistanchis herba ethanol extract concentrate through macroporous resin, sequentially eluting with water and ethanol solution 2, and collecting ethanol eluate to obtain Cistanchis herba extract.

Preferably, the volume percentage of the ethanol solution 1 or the ethanol solution 2 is 50-70%; the extraction mode is heating reflux, the extraction times are 1-3 times, and the extraction time is 1-3 hours each time.

Preferably, the density of the concentrated filtrate is 0.95 to 1.10g/cm ³ 。

Preferably, the model of the macroporous resin is D101; the dosage of the macroporous resin is 20-150 g.

Preferably, the mass ratio of the cistanche to the ethanol solution 1 is 1:1-12; the content of the water is 1-2 times of the column volume; the content of the ethanol solution 2 is 1-3 times of the column volume.

Preferably, the cistanche salsa extract comprises total cistanchis glycosides.

The invention also provides a cistanche deserticola extract prepared by the preparation method.

Compared with the prior art, the invention has the following beneficial effects:

the invention provides a preparation method of a cistanche extract, the cistanche extract and application thereof. In the preparation method, the cistanche alcohol extract is separated and purified by adopting macroporous resin, so that the active ingredients in the cistanche can be effectively extracted, wherein the content of echinacoside is 21.51 percent, the process is simple, and the extraction rate is high. The cistanche deserticola extract prepared by the invention can obviously inhibit PDE (PDE) ₅ The protein improves the activity of nitric oxide synthase, thereby effectively treating erectile dysfunction.

Drawings

FIG. 1 is a graph of echinacoside standard curve;

FIG. 2 is the static adsorption result of echinacoside content in Cistanchis herba extract after purification with macroporous resin of different types;

FIG. 3 is a graph showing the effect of different loading concentrations on the adsorption rate of macroporous resin;

FIG. 4 shows the effect of cistanche extracts of different treatment groups on NOS activity;

FIG. 5 is a graph of the effect of Cistanchis herba extract on PDE5 activity in different treatment groups;

FIG. 6 shows the PDE5 inhibition rate of cistanche deserticola extract in different treatment groups.

Detailed Description

In the invention, the medicament preferably takes the cistanche salsa extract as an active ingredient, and also preferably comprises a pharmaceutically acceptable carrier, wherein the carrier refers to one or more of conventional medicament carriers in the field of medicinal preparations, such as a filler, an adhesive, a disintegrating agent, a lubricant, a pigment, a flavoring agent, a solvent and a surfactant. The filler comprises one or more of starch, microcrystalline cellulose, sucrose, dextrin and lactose; the lubricant comprises magnesium stearate and/or sodium chloride; the adhesive comprises one or more of water, ethanol, syrup, hydroxypropyl methylcellulose and sodium carboxymethylcellulose; the solvent comprises water and/or a balanced salt solution; the binder preferably comprises one or more of ethanol, starch slurry, water, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose; the flavoring agent preferably comprises one or more of aspartame, sucrose, simple syrup, orange peel syrup, citric syrup, cherry syrup, stevioside, sorbitol, mannitol, acacia, gelatin, sodium alginate, and tartaric acid; the disintegrant comprises one or more of cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose and sodium carboxymethyl starch; the surfactant comprises one or more of polyethylene glycol, sodium lauryl sulfate and lauroyl glutamic acid. The pharmaceutical formulation of the present invention is preferably an oral dosage form. The oral dosage form is preferably pills, capsules, tablets, powder, granules or oral liquid, and more preferably tablets or capsules.

In the present invention, cistanche is pulverized, the origin of cistanche is preferably inner Mongolia, and the pulverized particle size is preferably 20 to 80 mesh. In the invention, the cistanche deserticola is crushed and then mixed with the ethanol solution 1, and the mass ratio of the cistanche deserticola to the ethanol solution 1 is preferably 1:1-12, and more preferably 1:5-11; the volume percentage of the ethanol solution 1 is preferably 50 to 70%. The mixing method of the present invention is not particularly limited as long as the mixing is uniform, such as stirring, shaking or swirling. In the invention, after mixing with the ethanol solution 1, extracting, filtering and concentrating the filtrate, wherein the extraction mode is preferably heating reflux, the extraction frequency is preferably 1 to 3 times, more preferably 2 times, and the extraction time is preferably 1 to 3 hours, more preferably 1.5 to 2.5 hours each time; the density of the concentrated filtrate is preferably 0.95 to 1.10g/cm ³ The density of the concentrated filtrate is adjusted, so that the adsorption rate in the subsequent macroporous resin purification is improved, and the efficiency of treating erectile dysfunction is improved; the filtration can be selected from centrifugation, suction filtration or sieving; the concentration is preferably a concentration under reduced pressure. In the invention, the cistanche alcohol-extracted concentrated solution is obtained after concentrating the filtrate, and is processed by macroporous resin, and then water and ethyl are sequentially usedEluting with alcoholic solution 2, and collecting ethanol eluate to obtain Cistanchis herba extract. The type of the macroporous resin is preferably D101, and the method has high efficiency of adsorbing, resolving and recovering the cistanche salsa extract by adopting the macroporous resin D101; the dosage of the macroporous resin is preferably 20-150 g, and more preferably 24-28 g; the volume percentage of the ethanol solution 2 is preferably 50 to 70 percent. The content of the water is preferably 1 to 2 times of the column volume, and more preferably 1 time of the column volume; the content of the ethanol solution 2 is preferably 1 to 3 times the column volume, and more preferably 2 times the column volume. In the invention, the cistanche deserticola extract comprises total cistanche deserticola glycosides, wherein the content of echinacoside is more than 21 percent. In the present invention, total oligosaccharides from cistanche deserticola are removed by elution with water. In the invention, after the ethanol eluent is collected, the steps of reduced pressure concentration and drying are also included.

The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.

Example 1

A method for preparing Cistanchis herba extract comprises the following steps:

(1) Mixing 60 mesh Cistanchis herba powder 5kg with 10 times of 60% ethanol solution, heating and refluxing for 2 hr each time, extracting twice, sieving with 100 mesh sieve, mixing filtrates, and concentrating the filtrate under reduced pressure to 1.02g/cm ³ To obtain the cistanche alcohol extraction concentrated solution;

(2) Extracting the obtained herba cistanches with alcohol to obtain concentrated solution, and concentrating to 4000rm min ^-1 Centrifuging, collecting supernatant, and collecting filtered alcoholic extract of Cistanchis herba;

(3) Soaking D101 macroporous resin in 95% ethanol for 24 hr, swelling, eluting with 95% ethanol until the eluate is not white and turbid, eluting with ultrapure water until no alcohol smell is observed, filtering, and adjusting the density to 1.02g/cm ³ Extracting Cistanchis herba with ethanol, concentrating, passing through 25g D101 macroporous resin, sequentially eluting with water and 60% ethanol solution, and collectingCollecting ethanol solution eluate, concentrating under reduced pressure, and drying to obtain Cistanchis herba extract.

Example 2

This example is different from example 1 in that in step (3) of this example, the density after filtration was set to 1.00g/cm ³ The concentrated solution of the cistanche alcohol extraction is processed by 25g D101 macroporous resin, and the rest steps are the same as the example 1.

Example 3

This example is different from example 1 in that in step (3) of this example, the density after filtration was 1.02g/cm ³ The concentrated solution of the ethanol extraction of the cistanche deserticola passes through 100g D101 macroporous resin, and the rest steps are the same as the example 1.

Example 4

This example is different from example 3 in that in step (3) of this example, the density after filtration was 1.02g/cm ³ The cistanche alcohol-extracted concentrated solution passes through 50g D101 macroporous resin, and is eluted by water with the volume of one time of that of the macroporous resin column and 50 percent ethanol solution with the volume of two times of that of the macroporous resin column in sequence, and the rest steps are the same as the steps in the example 3.

Example 5

This example is different from example 3 in that in step (3) of this example, the density after filtration was 1.04g/cm ³ The concentrated solution of the ethanol extraction of the cistanche deserticola passes through 50g D101 macroporous resin, and the rest steps are the same as the example 3.

Example 6

This example is different from example 3 in that in step (3) of this example, the density after filtration was 1.06g/cm ³ The concentrated solution of the ethanol extraction of the cistanche deserticola passes through 50g D101 macroporous resin, and is sequentially eluted by water with the volume of one time of the macroporous resin column and 70 percent ethanol solution with the volume of two times of the macroporous resin column, and the rest steps are the same as the step of the embodiment 3.

Example 7

This example is different from example 3 in that in step (3) of this example, the density after filtration was 1.04g/cm ³ Passing the concentrated alcoholic extractive solution of Cistanchis herba through 100g D101 macroporous resin, sequentially eluting with water and 70% ethanol solution, which are twice the volume of macroporous resin column, and purifying with ethanolThe remaining procedure was the same as in example 3.

Example 8

This example is different from example 3 in that in step (3) of this example, the density after filtration was 1.06g/cm ³ The concentrated ethanol extract of cistanche deserticola passes through 100g D101 macroporous resin, and is eluted by water with the volume of one time of the macroporous resin column and 50 percent ethanol solution with the volume of two times of the macroporous resin column in sequence, and the rest steps are the same as the example 3.

Example 9

This example is different from example 3 in that in step (3) of this example, the density after filtration was 1.02g/cm ³ The concentrated ethanol extract of cistanche deserticola passes through 150g of D101 macroporous resin, and is sequentially eluted by water with the volume of one time of the macroporous resin column and 70 percent ethanol solution with the volume of two times of the macroporous resin column, and the rest steps are the same as the example 3.

Example 10

This example is different from example 3 in that in step (3) of this example, the density after filtration was 1.04g/cm ³ The concentrated ethanol extract of cistanche deserticola passes through 150g of D101 macroporous resin, and is sequentially eluted by water with the volume of one time of the macroporous resin column and 50 percent ethanol solution with the volume of two times of the macroporous resin column, and the rest steps are the same as the example 3.

Example 11

This example is different from example 3 in that in step (3) of this example, the density after filtration was 1.06g/cm ³ The concentrated ethanol extract of cistanche deserticola passes through 150g of D101 macroporous resin, and is sequentially eluted by water with the volume of one time of the macroporous resin column and 60 percent ethanol solution with the volume of two times of the macroporous resin column, and the rest steps are the same as the example 3.

Example 12

This example is different from example 1 in that in step (3) of this example, the density after filtration was 1.04g/cm ³ The concentrated solution of the cistanche alcohol extraction is processed by 25g D101 macroporous resin, and the rest steps are the same as the example 1.

Example 13

This example is different from example 1 in that in step (3) of this example, the density after filtration was 1.06g/cm ³ The concentrated solution of the cistanche alcohol extraction is processed by 25g D101 macroporous resin, and the rest steps are the same as the example 1.

Comparative example 1

The comparative example differs from example 1 in that the macroporous resin of the comparative example is AB-8 macroporous resin, and the rest of the procedure is the same as example 1.

Comparative example 2

The comparative example is different from example 1 in that the macroporous resin of the comparative example is HPD100 macroporous resin, and the rest of the procedure is the same as example 1.

Comparative example 3

The comparative example is different from example 1 in that the macroporous resin of the comparative example is HPD500 macroporous resin, and the rest of the procedure is the same as example 1.

Comparative example 4

The comparative example is different from example 1 in that the macroporous resin of the comparative example is HPD910 macroporous resin, and the rest of the procedure is the same as example 1.

Comparative example 5

The difference between the comparative example and the example 2 is that in the step (3) of the comparative example, the cistanche alcohol extract concentrated solution with the sample loading concentration of 0.5mg/mL is processed by 25g D101 macroporous resin, and the rest steps are the same as the example 2.

Comparative example 6

The difference between the comparative example and the example 2 is that in the step (3) of the comparative example, the cistanche alcohol extract concentrated solution with the sample loading concentration of 1.5mg/mL is processed by 25g D101 macroporous resin, and the rest steps are the same as the example 2.

Comparative example 7

The difference between the comparative example and the example 2 is that in the step (3) of the comparative example, the cistanche alcohol extract concentrated solution with the sample loading concentration of 2.0mg/mL is processed by 25g D101 macroporous resin, and the rest steps are the same as the example 2.

Comparative example 8

The difference between the comparative example and the example 2 is that in the step (3) of the comparative example, the cistanche alcohol extract concentrated solution with the sample loading concentration of 2.5mg/mL is processed by 25g D101 macroporous resin, and the rest steps are the same as the example 2.

Test example 1

1.1 the content of echinacoside in the obtained cistanche extract is measured by adopting an ultraviolet spectrophotometry and taking echinacoside as a reference.

(1) And (3) preparing a standard curve: taking 10mg echinacoside, adding 50% methanol solution, fixing the volume to a 100mL volumetric flask, making into 0.05mg/mL, 0.04mg/mL, 0.03mg/mL, 0.02mg/mL and 0.01mg/mL, scanning by using a full wavelength of an ultraviolet visible spectrometer to obtain lambda max =332nm, measuring the absorbance A of the standard solution at the lambda max wavelength, and obtaining a regression equation and a linear range by using A as a vertical coordinate and C as a horizontal coordinate of a standard curve.

(2) And measuring the absorbance of the echinacoside in the cistanche extract to be measured by adopting an ultraviolet spectrophotometry, and further calculating the content of the echinacoside in the cistanche extract to be measured.

The echinacoside standard curve is shown in FIG. 1, and the absorbance of echinacoside at different concentrations is shown in Table 1.

TABLE 1 absorbance of echinacoside at different concentrations

As shown in FIG. 1 and Table 2, the formula of the echinacoside standard curve is y =17.18x +0.0364, R ² =0.9991; the linear range of absorbance is 0.202-0.898.

1.2 the content of echinacoside in the cistanche extract prepared in example 1 was measured by uv spectrophotometry as described in 1.1.

The results showed that the content of echinacoside in the cistanche extract prepared in example 1 was 21.51%.

1.3 the cistanche extracts prepared in example 1 and comparative examples 1-4 are respectively prepared into 1.5mg/mL sample solution to be tested by 50% methanol solution, and the echinacoside content in the cistanche extracts prepared in example 1 and comparative examples 1-4 is determined by the ultraviolet spectrophotometry method described in 1.1. Calculation of adsorption Rate = (C) ₁ V ₁ -C ₂ V ₂ )/(C ₁ V ₁ ×100％)，C ₁ (mg/mL) is the concentration of total saponins in the sample solution before adsorption; v ₁ (mL) is the volume of sample solution before adsorption; c ₂ (mg/mL) is the concentration of total saponins in the effluent after adsorption; v ₂ (mL) is the volume of the effluent after adsorption, and 70% ethanol is added into the filter residue (the resin after filtration), the mixture is fully shaken and kept stand for 12h, and then the mixture is filtered. Measuring the absorbance of the filtrate, calculating the content of total saponins in herba cistanches Deserticolae, and calculating the desorption rate = C ₃ V ₃ /(C ₁ V ₁ -C ₂ V ₂ )×100％，C ₃ (mg/mL) is the concentration of total saponins in the desorption solution; v ₃ (mL) is the volume of the stripping solution. Calculated recovery = adsorption × desorption.

The results in FIG. 2 show that the static adsorption results after purification with D101 macroporous resin are optimal.

1.4 Effect of different loading concentrations on the adsorption Rate of macroporous resins

The respective adsorption rates of the cistanche extracts prepared in example 2 and comparative examples 4 to 8 were measured according to the method described in 1.3.

As can be seen from FIG. 3, the adsorption rate was maximized when the concentration of the filtered alcoholic concentrate of cistanche was 1.0 mg/mL.

1.5 the influence of different ethanol solutions (ethanol solution during elution), different dosage of macroporous resin and sample loading concentration on the content of the active ingredients of the cistanche deserticola extract.

The echinacoside content in the cistanche extracts prepared in example 3 and comparative examples 9 to 16 was measured by uv spectrophotometry as described in 1.1 and calculated as the ratio, where ratio = total amount/total amount of solids × 100%, and the results are shown in table 2.

TABLE 2 results of echinacoside content in cistanche extracts in different groups

As can be seen from table 2, the cistanche deserticola extract prepared in example 3 has the highest echinacoside content.

Test example 2

Protein PDE ₅ Closely related to the erection function of the penis, the down-regulation of the protein of the penis activates the cavernous body congestion of the penis, thereby leading the penis to be erected. Nitric oxide synthase NOS, which is responsible for catalyzing arginine to generate NO, then NO diffuses to peripheral vascular smooth muscle cells to activate GC, so that GTP is converted into cGMP, the intracellular cGMP is increased, the cGMP reduces the calcium ion concentration in the vascular smooth muscle cells by inhibiting related kinases, finally, blood vessels are dilated, the sponge body is filled with blood, and meanwhile, venous reflux is compressed, so that the sponge body is further congested, and the erectile function is maintained. In the study of strengthening yang, male SD rat and IMR-32 cell line are selected to obtain clinical study effect.

1. Laboratory animal

Male SD rats, 5, 180-220g, SPF grade. The experimental animals are selectively bred in a barrier environment, the license number of an experimental unit is SYXK (Jing) 2019-0003, the rats are bred adaptively for 3 days before the experiment, the temperature is 21.5-22.8 ℃, the relative humidity is 53.5-56.5%, the light and dark period illumination is carried out for 12h, and the animals freely drink purified water.

2. Experimental Material

(1) And (3) testing the sample:

the cistanche extracts obtained in example 1, example 12 and example 13 (subsequently named 1.02, 1.04 and 1.06 in this order) and the cistanche alcohol-extracted concentrate obtained in step (1) of example 1 (named alcohol 60) were used.

(2) Positive control drug: sildenafil.

(3) Blank group: physiological saline

3. Dosage and configuration of administration

(1) The dosage of the test sample is 1.8g/kg.

(2) Dosage of positive control drug

Sildenafil: the administration dose of rats was 0.3g/70kg × 70kg × 0.018/0.2kg =0.027g/kg, calculated on the basis of the human dose of 60 mg/human/day, calculated on the basis of the reduction of the surface area of human and animal intermediates and the recommended production concentration of drug-containing serum.

(3) Drug configuration

(a) 2.7mg/mL sildenafil solution

1 piece of sildenafil (the content of sildenafil is 30 mg/piece) is taken and dissolved in 11.11mL of normal saline, and the mixture is stirred uniformly and is ready to use.

(b) 180mg/mL test article

Respectively weighing 1.8g of test sample, dissolving in 8mL of normal saline, diluting to 10mL, and mixing.

4. Experiment grouping

In the yang-strengthening experiment, the administration of animals is divided into six groups, namely a blank group, a sildenafil group, a cistanche salsa group 1.02, a cistanche salsa group 1.04, a cistanche salsa group 1.06 and an alcohol group 60.

5. Statistical treatment

The differences between groups of the experiment were compared by One-way ANOVA test, statistical analysis and data processing using Graphpad Prism5 software.

6. Experimental methods and results

After fasting for 12 hours, SD rats were gavaged at 1mL/100 g. One hour after administration, rats were anesthetized, and blood was taken from the abdominal aorta and serum was isolated. Heating in water bath at 56 deg.C for 30 min, filtering with 0.22 μm filter membrane, and storing at-20 deg.C. Or directly preparing culture medium according to 10% concentration serum amount, and standing at 4 deg.C for use.

The activity of NOS or PDE5 in rat serum was determined using the method described in the ELISA kit instructions. The results are shown in FIGS. 4 to 6.

The results of fig. 4 show that the cistanche extract prepared by the present invention significantly increases NOS activity. Wherein, the effect of 1.02 passing through the column is equivalent to that of the positive medicine, the effects of 1.04 passing through the column both have a rising trend, and the effect of 1.06 passing through the column is not raised.

The results of fig. 5-6 show that the cistanche deserticola extract prepared by the invention can obviously inhibit PDE ₅ 1.02 column chromatography, 1.04 column chromatography, 1.06 column chromatography and 60 alcohol extraction for inhibiting PDE ₅ The activity effect of the compound is slightly better than that of a positive medicine.

Therefore, the cistanche salsa extract prepared by the invention is remarkableInhibit PDE ₅ The activity of the compound is better than that of a positive drug sildenafil, and the activity of NOS is obviously improved, so that the aim of efficiently treating erectile dysfunction is fulfilled.

The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.

Claims

1. Application of Cistanchis herba extract in preparing medicine for treating erectile dysfunction is provided.

2. Use of Cistanchis herba extract in preparing PDE ₅ The use of inhibitors.

3. Application of Cistanchis herba extract in preparing nitric oxide synthase activator is provided.

4. A method for preparing the cistanche deserticola extract as claimed in any one of claims 1 to 3, comprising the steps of:

5. The method according to claim 4, wherein the ethanol solution 1 or the ethanol solution 2 is 50 to 70% by volume; the extraction mode is heating reflux, the extraction times are 1-3 times, and the extraction time is 1-3 hours each time.

6. The method according to claim 4, wherein the density of the concentrated filtrate is 0.95 to 1.10g/cm ³ 。

7. The preparation method according to claim 4, wherein the macroporous resin is D101; the dosage of the macroporous resin is 20-150 g.

8. The preparation method according to claim 4, wherein the mass ratio of the cistanche deserticola to the ethanol solution 1 is 1:1-12; the water content is 1-2 times of the column volume; the content of the ethanol solution 2 is 1-3 times of the column volume.

9. The method of claim 4, wherein the cistanche extracts comprise total glycosides of cistanche deserticola.

10. A cistanche salsa extract prepared by the preparation method of any one of claims 4-9.